Stockscreener 앱 받기
3.16
4.64%
0.14
전일 마감가:
$3.02
열려 있는:
$3.02
하루 거래량:
7,780
Relative Volume:
0.16
시가총액:
$13.75M
수익:
$1.41M
순이익/손실:
$-9.84M
주가수익비율:
-1.4761
EPS:
-2.1408
순현금흐름:
$-7.85M
1주 성능:
-8.93%
1개월 성능:
+13.06%
6개월 성능:
+6.76%
1년 성능:
-30.85%
1일 변동 폭
$3.02
$3.32
1주일 범위
$2.99
$3.60
52주 변동 폭
$2.15
$5.0632
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.16 | 13.75M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-05-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-02-13 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-08-17 | 재확인 | Maxim Group | Buy |
| 2015-07-27 | 재확인 | ROTH Capital | Buy |
| 2015-06-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Morningstar
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Operating cash flow per share of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx launches trial of brain cancer drug GLIX1 By Investing.com - Investing.com South Africa
BioLineRx initiates Phase 1/2a study of GLIX1 - tipranks.com
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - investing.com
BioLineRx provides corporate update - tipranks.com
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips - Investing.com
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Finviz
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model - TipRanks
Going concern and debt pressures at BioLineRx (NASDAQ: BLRX) - Stock Titan
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings - Sahm
BioLineRx to Report 2025 Annual Results on March 23, 2026 - Finviz
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - The Globe and Mail
Bioline Rx Ltd Adr (BLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):